Weekly Aesthetic Medicine Roundup: TikTok and Xiaohongshu Crack Down on Medical Aesthetics; Multiple Companies Release 2024 Earnings; Jiangsu Wuzhong Investigated for Alleged Disclosure Violations

Mar 02, 2025 17:20 CST Updated 17:20

Bloomage Biotech

Developer of bioactive substance products, producer of hyaluronic acid raw materials

Medlander

Developer of Intelligent Pelvic Floor Rehabilitation Diagnosis and Treatment System Products

VISHEE

Developer, Manufacturer, and Distributor of Rehabilitation Medical Devices

Click the ? card below to follow me

Bloomage Biotech's Net Profit in 2024 is 164 Million Yuan, Decreased by 72.27% Year-on-Year

On the evening of February 27, Bloomage Biotech (688363) released its earnings快报, showing that in 2024, the company achieved a total operating revenue of 5.371 billion yuan, a year-on-year decrease of 11.6%; the corresponding归属net profit was 164 million yuan, a year-on-year decrease of 72.27%.

Bloomage Biotech stated that during the reporting period, the company's functional skincare business, which accounts for a relatively high proportion of its revenue, has been affected by factors such as intensified market competition, industry cycle fluctuations, and strategic adjustments. The adjustment is still ongoing, and the functional skincare business is expected to bottom out in 2025.(Source:Beijing Business Today ）

丨Medlander's Revenue Grew by 24.02% in 2024

On February 26, Medlander released its 2024 earnings report. During the reporting period, the company's total operating revenue was 423 million yuan, a year-on-year increase of 24.02%; operating profit was 113 million yuan, a year-on-year increase of 10.06%; total profit was 123 million yuan, a year-on-year increase of 21.66%; net profit attributable to the parent company's owners was 102 million yuan, a year-on-year increase of 13.75%; net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 90.4377 million yuan, a year-on-year increase of 26.42%. The main factors affecting operating performance were the company’s strengthened brand building, optimized sales channels, and rapid growth in sales of reproductive rehabilitation products, consumables, and accessories.(Source:Beijing News )

丨VISHEE: Medical Aesthetics Engine Drives New Growth Momentum

On the evening of February 26, 2025, Nanjing Vishee Medical Technology Co., Ltd. (Company Code: 688580, hereinafter referred to as "VISHEE" or "the Company") released its 2024 annual earnings快报, closing with a robust performance of 400 million yuan in operating revenue and 100 million yuan in net profit attributable to shareholders. Amidst industry transformations and market challenges, the company, leveraging deep technological expertise and strategic resilience, enhanced its risk resistance capabilities. By expanding its portfolio of high-end products and achieving breakthroughs in the medical aesthetics sector, VISHEE has injected strong momentum into its high-quality development.

Notably, in 2024, VISHEE's medical aesthetics segment performed particularly well, with significant sales increases in two products—body-sculpting magnetic stimulation devices and high-frequency electrocautery instruments—becoming a key driver of revenue growth.(Source:China Fortune Network )

丨Jinbo Biotech Releases New Product “VIEME® 164.88° ColNet Collagen Network”

Reporters learned from Jinbo that the company's new product "VIYMEE® 164.88° ColNet Collagen Network" was officially released on February 18.

According to Yang Xia, Chairman of Jinbo, the formation of the collagen network is the core mechanism by which humanized collagen functions within the human body. This product achieves multi-level, multi-functional, and strong support, making it applicable across various fields. The newly released recombinant humanized collagen product by Jinbo not only offers new options for the medical aesthetics field but also demonstrates potential in medical scenarios such as cardiovascular repair and tissue regeneration. Yang Xia also revealed that the company is collaborating with multiple medical institutions to explore the application of collagen in organ repair, anti-aging, and other areas.(Source:(Shanghai Securities News · China Securities Network)

丨Weak Performance Growth: Aimeike Director Wang Lanzhu Plans to Cash Out Over 400 Million Yuan

On February 24, Aimeide (300896) released an attention-grabbing announcement. The company's director, Wang Lanzhu, plans to reduce his holdings by no more than 2,298,500 shares through centralized bidding or block trading between March 17 and June 16, 2025, accounting for 0.76% of the company’s total share capital. The reason for the reduction is personal financial needs. This news undoubtedly caused a stir in the capital market and also sparked investors' thoughts on Aimeide’s future development. Following the announcement, Aimeide's stock price fell by more than 3%, clearly reflecting market concerns over executives’ share reductions. As of this video, Aimeide’s stock price was 176.96 yuan per share, down 3.53%. Based on this estimate, if Wang Lanzhu proceeds with the maximum planned reduction, he may cash out over 400 million yuan.(Source:(NetEase Finance)

Bloomage Biotech Granted Patent for "An Anti-Aging Composition and Its Application in Cosmetics"

According to the data displayed on Tianyancha APP, Bloomage Biotech (688363) has newly obtained an invention patent authorization. The patent is named "An Anti-Aging Composition and Its Application in Cosmetics," with the patent application number CN202211704135.7, and the authorization date is February 25, 2025.

Abstract: The present invention discloses an anti-aging composition and its application in cosmetics, wherein the composition comprises polyglutamic acid and its salts, hyaluronic acid and its salts, and sweet orange extract. The combination of polyglutamic acid and its salts, hyaluronic acid and its salts, and sweet orange extract according to the present invention has a synergistic effect, which can exhibit the efficacy of improving skin elasticity even when the total amount added is relatively low, thereby achieving the purposes of reducing wrinkles, firming skin, and anti-aging.(Source:Securities Star )

Eli Lilly rises over 2.7%, launches 10 mg dose vial of Zepbound

Eli Lilly's stock price rose over 2.7% after launching 10mg vial of Zepbound for weight loss and reducing prices for 2.5mg and 5mg versions; more than 10% of patients have started taking the lower dose of Zepbound.(Source:(Gelonghui)

Douyin Life Service Cracks Down on Illegal Medical Aesthetic Live Streams

On the afternoon of February 27, Douyin Life Service held the "Service Experience and Governance Open Day" and released the "2024 Douyin Life Service Consumer Rights Protection Annual Report," disclosing measures and phased achievements in consumer rights protection and ecosystem governance over the past year.

In 2024, the scale of lifestyle service content on Douyin experienced significant growth, with live streaming and short video submissions increasing by 94% and 78% year-on-year, respectively. The platform shifted its content governance approach from a singular focus on negative governance to a multi-objective model that balances merchant and influencer experience with the overall ecosystem health, fostering a vibrant and healthy content environment. Special campaigns were launched to address violations in medical aesthetics promotion and "low-cost tours," resulting in the removal of over 23,000 non-compliant medical aesthetics live streams and 2,565 "low-cost tour" live streams, significantly reducing industry violation rates. Additionally, comprehensive measures were implemented to combat false advertising, leading to the removal of more than 740,000 non-compliant short videos, penalizing over 420,000 creators, and achieving a 30% reduction in violation rates. Meanwhile, initiatives such as upgrading the creator credit system improved content quality, with high-quality creator rankings increasing by 63%.(Source:Sina Technology）

Xiaohongshu Launches New Round of Medical Aesthetics Governance Initiative: 500,000 Violating Posts Handled

On February 24, the official Xiaohongshu account "Shu Guanji" announced that the platform's latest medical aesthetics governance initiative focuses on addressing issues related to unauthorized medical aesthetics marketing, including risky引流 (traffic diversion), risky promotion, risky qualifications, and scientifically inaccurate claims. By strictly controlling problems such as exaggerated medical aesthetics results and scientific inaccuracies, the platform continues to enhance its ability to manage and warn against high-risk medical aesthetic practices. From October of last year to now, nearly 500,000违规 (non-compliant) posts have been handled, and more than 50,000 accounts have been banned.

In addition, in the field of live streaming, the scope of content recognition has been continuously expanded, and multimodal models and other identification methods have been introduced to enhance the ability to quickly detect and handle non-compliant medical aesthetics live streaming content. From October last year to now, a total of more than 2,400 non-compliant live streaming rooms have been handled, and multiple measures such as prohibiting live streaming and deducting account credibility points have been taken against 1,030 accounts.(Source:Interface News)

Jiangsu Wuzhong Pharmaceutical Development Co.,ltd. Investigated by CSRC for Suspected Violation of Information Disclosure Regulations

Announcement of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. on Receiving the Notice of Investigation from the China Securities Regulatory Commission and Risk Warning

The board of directors and all members of the board of this company guarantee that the announcement contains no false records, misleading statements, or significant omissions, and assume legal responsibility for the truthfulness, accuracy, and completeness of its content.

Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (hereinafter referred to as "the Company") received the "Notice of Investigation" (No. 0392025006) from the China Securities Regulatory Commission (hereinafter referred to as "CSRC") on February 26, 2025. Due to suspected violations of information disclosure regulations, the CSRC has decided to investigate the Company in accordance with laws and regulations such as the "Securities Law of the People's Republic of China" and the "Administrative Punishment Law of the People's Republic of China."

If the facts subsequently recognized by the China Securities Regulatory Commission's administrative penalties constitute a major illegal mandatory delisting scenario as stipulated in the "Shanghai Stock Exchange Listing Rules," the company's stock will be subject to major illegal mandatory delisting. Investors are advised to be aware of investment risks.(Source:Jiangsu Wuzhong Pharmaceutical Development Co.,ltd.

Customs Seizes Weight Loss Drugs Containing Methamphetamine Components and No Manufacturer Information

On February 20, Suzhou Customs under Nanjing Customs seized 180 packages, totaling 1,620 tablets, of unapproved weight-loss drugs through inbound postal channels. On-site rapid testing revealed that the tablets tested positive for methamphetamine. Methamphetamine is the active ingredient in crystal meth and is classified as a Schedule I psychotropic substance due to its addictive nature. The Customs has lawfully placed the drugs under temporary detention.(Source:Jiangsu News)